GlassScriptPhysician profile
Isaiah Steffen
NPI 1457707598
$2,191.79
in general payments reported to CMS, 2019-2025
30 companies · $858 in 2025
The $858 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.53 · 2020: $44.68 · 2021: $52.11 · 2022: $57.49 · 2023: $107 · 2024: $1,045 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,009.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $371.24 | 2024-2025 | |
| Novo Nordisk INC | $319.73 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $221.47 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $178.82 | 2024-2025 | |
| Pfizer INC. | $114.62 | 2020-2025 | |
| Radius Health, INC. | $102.16 | 2024-2025 | Tymlos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.83 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $61.56 | 2024-2025 | Rexulti |
| Abbott Laboratories | $56.97 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $52.74 | 2024-2025 | |
| Exact Sciences Corporation | $47.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $46.82 | 2024-2025 | Trintellix |
| Axsome Therapeutics, INC. | $46.77 | 2024 | Auvelity |
| Organon LLC | $44.91 | 2022-2023 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $44.45 | 2024-2025 | Farxiga |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $44.27 | 2025 | |
| Lundbeck LLC | $38.52 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $32.61 | 2023-2024 | Bexsero, Pediarix, Arexvy |
| Boston Scientific Corporation | $29.36 | 2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.94 | 2024-2025 | Jardiance |
| Alkermes, INC. | $28.16 | 2019-2020 | |
| Amgen INC. | $27.56 | 2024-2025 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.83 | 2024 | Xifaxan, Trulance |
| Ultragenyx Pharmaceutical INC. | $22.31 | 2024 | Crysvita |
| Harmony Biosciences LLC | $22.01 | 2025 | |
| Phathom Pharmaceuticals, INC. | $20.32 | 2025 | Voquezna |
| Inspire Medical Systems, INC. | $18.35 | 2025 | Inspire |
| Insmed, INC. | $17.26 | 2025 | Arikayce |
| Astellas Pharma US INC | $16.53 | 2024 | Veozah |
| Allergan, INC. | $14.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaiah Steffen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.